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Abstract: Blastic plasmacytoid dendritic cell neoplasm is a rare and aggressive hematodermic neoplasia with fre-
quent cutaneous involvement and leukemic dissemination. We report the case of a 76-year-old man with a 2
month history of violaceous nodules and a tumor with stony consistency, located on the head, and mandibular,
cervical and supraclavicular lymphadenopathies. Multiple thoracic and abdominal adenopathies were identified
on computerized tomography. Flow cytometry analysis of the skin, lymph node and bone marrow biopsies
demonstrated the presence of plasmocytoid dendritic cell neoplastic precursor cells (CD4+, CD45+, CD56+ and
CD123+ phenotype). After initial clinical and laboratorial complete remission with chemotherapy, the patient
died due to relapse of the disease associated with the appearance of a cervical mass with medullary compromise.
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Resumo: A neoplasia blástica de células dendríticas plasmocitóides é uma neoplasia hematodérmica rara, agres-
siva, com frequente envolvimento cutâneo e disseminação leucêmica. Relatamos o caso de um homem de 76 anos
com quadro clínico com 2 meses de evolução caracterizado por nódulos e tumor de tonalidade violácea, de con-
sistência pétrea, localizados na cabeça, e linfadenopatias mandibular, cervicais e supraclaviculares.
Identificaram-se múltiplas adenopatias torácicas e abdominais em tomografia computorizada. A análise por cito-
metria de fluxo de biópsias cutânea, ganglionar e óssea demonstrou a presença de precursores neoplásicos das
células dendríticas plasmocitóides (fenótipo CD4+, CD45+, CD56+ e CD123+). Após remissão clínica e laborato-
rial completa inicial com quimioterapia, veio a falecer por recaída da doença associada ao aparecimento de massa
cervical com compromisso medular.
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INTRODUCTION
Blastic plasmacytoid dendritic cell neoplasm
(BPDCN) was originally recognized in 1994, but the sub-
sequent lack of knowledge concerning its histogenesis
led to a succession of different designations such as
agranular CD4+ natural killer cell leukemia, blastic nat-
ural killer leukemia/lymphoma, agranular CD4+CD56+
hematodermic neoplasm or tumor.1-5 BPDCN is charac-
terized by predominant cutaneous involvement with
concomitant or ensuing spread to the bone marrow and
158
peripheral blood. It has a very aggressive clinical behav-
ior with short survivals.
CASE REPORT
A 76-year-old man was referred for evaluation
of various cutaneous lesions. He had a prior history of
total prostatectomy due to prostate adenocarcinoma 6
years before the current observation and myelodys-
plastic syndrome (MDS) presenting with neutropenia
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followed-up in hematology for 4 years. His neutrope-
nia had been extensively studied through imaging
studies and bone marrow aspirate and biopsy. MDS of
the refractory cytopenia with multilineage dysplasia
subtype was diagnosed and an expectant approach
with careful observation was undertaken.
Two months before referral, he progressively
developed multiple violaceous plaques and nodules
on the face and scalp. He denied any constitutional
symptoms and mentioned just a prior episode of
minor head trauma. The physical examination
revealed multiple well-demarcated, indurated plaques
and nodules scattered throughout the right frontotem-
poral and biparietal areas as well as a 7 cm wide tumor
in the anterior interparietal area (Figures 1 and 2).
Several mandibular, cervical and supraclavicular lym-
phadenopathies were noted. He was otherwise well,
which contrasted with the severity of the cutaneous
findings. Laboratory results revealed hemoglobin 127
g/L, white blood cell count 6.0 x 109/L with 55% lym-
phocytes; an additional decrease in neutrophils (0.7 x
109/L) and platelet count of 241 x 109/L were noted.
Lactate dehydrogenase was elevated at 1139 U/L.
Chest radiography was unremarkable. Thoraco-
abdomino-pelvic computerized tomography revealed
enlargement of several mediastinal, axillary, celiac,
retroperitoneal, obturator and inguinofemoral lymph
nodes (some larger than 25 mm).
Histology of skin and 2 cervical lymph nodes
revealed a monomorphous, non-epidermotropic dif-
fuse infiltration of small-to-medium sized cells with
pleomorphic nuclei (Figure 3) in the skin. This dense
infiltrate effaced the nodal architecture and was locat-
ed in the dermis and hypodermis, separated from the
epidermis by a grenz zone.
By immunohistochemistry, the cells coex-
pressed CD4, CD43, CD45 CD56, showed partial pos-
itivity for CD68 (Figures 4 and 5) and were negative
for CD3, CD5, CD8, CD20, CD30, CD34, CD38, CD117,
TDT, myeloperoxidase, light IgG chains and PAX5
(Figure 6). The proliferative index (Ki-67) was high,
approximately 60%.
Bone marrow biopsy showed a markedly
hypercellular marrow, with CD4+, CD43+,CD45+,
CD56+, CD123+ and HLA-DR+ small blast cells
accounting for 80% of cellularity. No expressions of
other T or B cell lineage were observed.
Based on clinical and laboratory findings, the
patient was diagnosed with BPDCN with extensive
cutaneous, nodal and bone marrow involvement.
Six cycles of CHOP (cyclophosphamide,
adryamicine, vincristine, and prednisolone) were pre-
scribed, with remission. Only post-therapy inflamma-
tory reactive lesions remained on the face and scalp.
FIGURE 1: Violaceous, stony tumor in the anterior 
interparietal region 
FIGURE 2: Multiple bilateral nodules and plaques in 
the parietal areas
FIGURE 3: Histology of the interparietal tumor revealed compact,
dermal and hypodermal infiltrate of non-epidermotropic mono-
morphous cells and blood extravasation (H&E´100)
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Two months later, the disease relapsed. Left-
sided brachial monoparesis developed and a paraver-
tebral cervical (C2-C3) mass with medullary compro-
mise through the intervertebral foramen was detected
on magnetic resonance imaging. The patient was hos-
pitalized in a status of rapid progression of the dise-
ase, with enlargement of the cervical mass, hyper-
leukocytosis (> 100.000/ml), mental status deteriora-
tion and died 7 months after the diagnosis (9 months
after onset of the first clinical symptoms).
DISCUSSION
The origin of BPDCN presumably lies in a
hematopoietic precursor of plasmacytoid dendritic
cells (DCs) of yet undefined lymphoid versus myeloid
lineage.6-8
It is a rare disease, typically manifesting in mid-
dle-aged or elderly men (although pediatric cases have
been reported).6 The clinical picture and progression of
BPDCN consist of two main patterns. In 90% of cases,
there is an indolent installation of cutaneous lesions
followed later by dissemination, whereas in the
remaining 10% it presents as advanced leukemia with
systemic involvement from the start. Previous exis-
tence of MDS has also been reported in a few cases.6
The presence of multiple skin lesions is a fea-
ture of both patterns described, found in over 90% of
BPDCN cases.3,6 Isolated skin lesions are also detected
in over half of cases.3 Skin involvement may display a
nodular or a patch and bruise-like lesion presentation,
with a thicker neoplastic infiltrate in the former and a
perivascular arrangement in the latter.3 In both cases,
a diffuse and monomorphous dermal infiltrate of
medium-sized cells, with an obvious blastic morphol-
ogy and epidermal sparing is reported.9
The diagnosis requires the demonstration of
CD4 and CD56, together with markers more restricted
to plasmacytoid dendritic cells (such as CD123) and
negativity for lymphoid, NK and myeloid lineage-
associated antigens.4,8
In our patient’s bone marrow flow cytometry,
cells were CD4+, CD45+, CD56+ and CD123+ and
lacked lineage-specific antigens. This phenotype,
albeit with specific isoform CD45RA positivity, ren-
ders it highly specific, as published.10
Researchers debate whether tumor cells are orig-
inally sited in the bone marrow or skin. Unresolved
questions remain regarding its histogenesis and aggres-
sive clinical presentation that commonly affects both
sites either consecutively or simultaneously.
Furthermore, the existence of rapidly disseminating dis-
ease cases and those with primarily cutaneous disease
and indolent progression raise questions to whether this
represents two stages of a disease spectrum or 2 differ-
ent CD4+CD56+ malignancies.6 Cutaneous tropism of
blast cells may explain frequent skin localization.6
BPDCN has an aggressive clinical behavior
despite an initial apparent indolence. The median sur-
vival is approximately 12-14 months.
Cognizant of our patient’s age, CHOP
chemotherapy was undertaken. The patient initially
FIGURE 4: Diffuse infiltration by strongly positive tumor 
cells highlighting grenz zone (CD4 ×200)
FIGURE 5: Diffuse infiltration by positive tumor cells (CD56 ×200) 
FIGURE 6: Diffuse infiltration by positive tumor cells (CD56 ×200) 
How to cite this article: Lencastre A, Cabete J, João A, Farinha P, Ferreira G, Lestre S. Blastic Plasmacytoid Dendritic
Cell Neoplasm. An Bras Dermatol. 2013;88(6 Suppl 1):S158-61.
REFE REN CES
Facchetti F, Jones D, Petrella T. Blastic plasmacytoid dendritic cells neoplasm. In1.
Swerdlow S, Campo E, Vardiman J, editors. WHO classification of Tumours of
Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: International Agency for
Research on Cancer; 2008. p. 145-7.
Adachi M, Maeda K, Takekawa M, Hinoda Y, Imai K, Sugiyama S, et al. High expres-2.
sion of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am J
Hematol.  1994;47:278-82.
Petrella T, Bagot M, Willemze R, Beylot-Barry M, Vergier B, Delaunay M, et al. Blastic3.
NK-Cell Lymphomas (Agranular CD4+CD56+ Hematodermic Neoplasms). Am J
Clin Pathol.  2005; 123:662-75.
Facchetti F, Ungari M, Marocolo D, Lonardi S, Vermi W. Blastic plasmacytoid dendri-4.
tic cell neoplasm. Haematol Meet Rep. 2009;3:1-3.
Sanches Jr J, Moricz C, Festa Neto C. Lymphoproliferative processes of the skin: part5.
2 - cutaneous T-cell and NK-cell lymphomas. An Bras Dermatol. 2006;81:7-25.
Feuillard J, Jacob MC, Valensi F, Maynadié M, Gressin R, Chaperot L, et al. Clinical6.
and biological features of CD4+ CD56+ malignancies. Blood. 2002;99:1556-63.
Petrella T, Comeau MR, Maynadié M, Couillault G, De Muret A, Maliszewski CR, et al.7.
Agranular CD4+ CD56+ hematodermic neoplasm (blastic NK-cell lymphoma) ori-
ginates from a population of CD56+ precursor cells related to plasmocytoid mono-
cytes. Am J Surg Pathol. 2002;26:852-62.
Piña-Oviedo S, Herrera-Medina H, Coronado H, Del Valle L, Ortiz-Hidalgo C.8.
CD4+/CD56+ hematodermic neoplasm: presentation of 2 cases and review of the
concept of an uncommon tumor originated in plasmacytoid dendritic cells expressing
CD123 (IL-3 receptor alpha). Appl Immunohistochem Mol Morphol. 2007;15:481-6.
Petrella T, Dalac S, Maynadié M, Mugneret F, Thomine E, Courville P, et al. CD4+9.
CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Français
d'Etude des Lymphomes Cutanés (GFELC). Am J Surg Pathol.  1999; 23:137-46.
Trimoreau F, Donnard M, Turlure P, Gachard N, Bordessoule D, Feuillard J. The CD4+10.




Alameda de Santo António dos Capuchos 
1169-050 - Lisboa - Portugal
E-mail: lencastre.derm@gmail.com
An Bras Dermatol. 2013;88(6 Suppl 1):158-61.
Blastic plasmacytoid dendritic cell neoplasm 161
responded favorably, as described in the
literature.3,6 As also reported, he had a fast and aggres-
sive relapse and died in a state of hyperleukocytosis
(> 100 x 109/L) with a symptomatic central nervous
system lesion, deemed secondary to his BPDCN.
Currently, there is no apparent consensus for
the optimal treatment of BPDCN. Intensive therapy
for acute leukemia increases the rate of sustained
complete remission. However, only myeloablative
treatment with allogenic bone marrow transplanta-
tion within the first remission has resulted in a better
chance of longer survival.6 q
